|
1
|
Tiollais P, Pourcel C and Dejean A: The
hepatitis B virus. Nature. 317:489–495. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minor MM and Slagle BL: Hepatitis B virus
HBx protein interactions with the ubiquitin proteasome system.
Viruses. 6:4683–4702. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Franchis R, Hadengue A, Lau G, Lavanchy
D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés
J, et al: EASL International Consensus Conference on Hepatitis B.
13–14 September, 2002 Geneva, Switzerland. Consensus statement
(long version). J Hepatol. 39 Suppl 1:S3–S25. 2003.PubMed/NCBI
|
|
4
|
Inchauspé G and Michel ML: Vaccines and
immunotherapies against hepatitis B and hepatitis C viruses. J
Viral Hepat. 14 Suppl 1:S97–S103. 2007. View Article : Google Scholar
|
|
5
|
Lu M, Menne S, Yang D, Xu Y and Roggendorf
M: Immunomodulation as an option for the treatment of chronic
hepatitis B virus infection: Preclinical studies in the woodchuck
model. Expert Opin Invest Drugs. 16:787–801. 2007. View Article : Google Scholar
|
|
6
|
Michel ML and Tiollais P: Hepatitis B
vaccines: Protective efficacy and therapeutic potential. Pathol
Biol (Paris). 58:288–295. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roggendorf M and Lu M: Woodchuck Hepatitis
Virus. 2007. View Article : Google Scholar
|
|
8
|
Garcia ML: Regulation of hepatitis B virus
replication by the ubiquitin-proteasome pathway (unpublished PhD
thesis)Yale University School of Medicine. New Haven, CT: 2010
|
|
9
|
Xiao X, Zhao P, Rodriguez-Pinto D, Qi D,
Henegariu O, Alexopoulou L, Flavell RA, Wong FS and Wen L:
Inflammatory regulation by TLR3 in acute hepatitis. J Immunol.
183:3712–3719. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keil JM, Shen Z, Briggs SP and Patrick GN:
Regulation of STIM1 and SOCE by the ubiquitin-proteasome system
(UPS). PLoS One. 5:e134652010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cacciapuoti F: Role of
ubiquitin-proteasome system (UPS) in left ventricular hypertrophy
(LVH). Am J Cardiovasc Dis. 4:1–5. 2014.PubMed/NCBI
|
|
12
|
Mata-Cantero L, Lobato-Gil S, Aillet F,
Lang V and Rodriguez MS: The Ubiquitin-Proteasome System (UPS) as a
cancer drug target: Emerging mechanisms and therapeuticsStress
Response Pathways in Cancer: From Molecular Targets to Novel
Therapeutics. Wondrak GT: Springer Netherlands; Dordrecht: pp.
225–264. 2015
|
|
13
|
Gao YQ, Yao Y and Li M: Effect of bushen
recipe on the immune effector molecules of natural killer cells in
patients with chronic hepatitis B. Zhongguo Zhong Xi Yi Jie He Za
Zhi. 30:710–713. 2010.(In Chinese). PubMed/NCBI
|
|
14
|
Chen XF, Chen SH, Gui-Yuan L, Xiao LW and
Lou ZH: Research and discussion on mechanism of treating
osteoporosis by Bushen Huoxue Recipe. Chin Tradit Pat Med.
33:1130–1134. 2011.
|
|
15
|
Tan Y, Tan L, Huang S, Lu J and Yu L:
Content determination of active component in Huangqi Yinyanghuo
group and its effects on hTERT and Bcl-2 protein in osteosarcoma. J
Anal Methods Chem. 2014:7693502014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo HY: Clinical research of using Bushen
Huoxue prescription in the treatment of early diabetic nephropathy.
Sci Technol Eng. 8:2176–2179. 2008.
|
|
17
|
Zhang E and Lu M: Toll-like receptor
(TLR)-mediated innate immune responses in the control of hepatitis
B virus (HBV) infection. Med Microbiol Immunol. 204:11–20. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cortez M, Carmo LS, Rogero MM, Borelli P
and Fock RA: A high-fat diet increases IL-1, IL-6, and TNF-α
production by increasing NF-κB and attenuating PPAR-γ expression in
bone marrow mesenchymal stem cells. Inflammation. 36:379–386. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guinn Z, Brown DM and Petro TM: Activation
of IRF3 contributes to IFN-γ and ISG54 expression during the immune
responses to B16F10 tumor growth. Int Immunopharmacol. 50:121–129.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coluccio C, Begini P, Marzano A,
Pellicelli A, Imperatrice B, Anania G, Delle Fave G and Marignani
M: Hepatitis B in patients with hematological diseases: An update.
World J Hepatol. 9:1043–1053. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stanley M: Tumour virus vaccines:
Hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond
B Biol Sci. 372:201602682017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stasi C, Silvestri C and Voller F:
Emerging trends in epidemiology of hepatitis B virus infection. J
Clin Transl Hepatol. 5:272–276. 2017.PubMed/NCBI
|
|
23
|
Guidotti LG, Ishikawa T, Hobbs MV, Matzke
B, Schreiber R and Chisari FV: Intracellular inactivation of the
hepatitis B virus by cytotoxic T lymphocytes. Immunity. 4:25–36.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guidotti LG, Rochford R, Chung J, Shapiro
M, Purcell R and Chisari FV: Viral clearance without destruction of
infected cells during acute HBV infection. Science. 284:825–829.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guidotti LG and Chisari FV: Noncytolytic
control of viral infections by the innate and adaptive immune
response. Annu Rev Immunol. 19:65–91. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Robek MD, Wieland SF and Chisari FV:
Inhibition of hepatitis B virus replication by interferon requires
proteasome activity. J Virol. 76:3570–3574. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wieland SF, Eustaquio A, Whitten-Bauer C,
Boyd B and Chisari FV: Interferon prevents formation of
replication-competent hepatitis B virus RNA-containing
nucleocapsids. Proc Natl Acad Sci USA. 102:9913–9917. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X,
Wei L, Chang J, Block TM and Guo JT: Interferons accelerate decay
of replication-competent nucleocapsids of hepatitis B virus. J
Virol. 84:9332–9340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Biermer M, Puro R and Schneider RJ: Tumor
necrosis factor alpha inhibition of hepatitis B virus replication
involves disruption of capsid Integrity through activation of
NF-kappaB. J Virol. 77:4033–4042. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Puro R and Schneider RJ: Tumor necrosis
factor activates a conserved innate antiviral response to hepatitis
B virus that destabilizes nucleocapsids and reduces nuclear viral
DNA. J Virol. 81:7351–7362. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen JJ: The Anti-HBV constituents from
traditional chinese medicine of swertia mileensis. Planta Med.
79:OP232013. View Article : Google Scholar
|
|
32
|
Dai XQ, Cai WT, Wu X, Chen Y and Han FM:
Protocatechuic acid inhibits hepatitis B virus replication by
activating ERK1/2 pathway and down-regulating HNF4α and HNF1α in
vitro. Life Sci. 180:68–74. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang Y, Jiang HY, Shi Y, He JL, Su S and
Chen Z: Chinese herbal medicine for carriers of the hepatitis B
virus: An updated systematic review and meta-analysis. Pharmazie.
69:723–730. 2014.PubMed/NCBI
|
|
34
|
Dai JJ, Tao HM, Min QX and Zhu QH:
Anti-hepatitis B virus activities of friedelolactones from Viola
diffusa Ging. Phytomedicine. 22:724–729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qiao B, Zhou ZH, Man LI, Sun XH, Jin SG,
Zhu XJ, Huang LY, Zhang X and Gao YQ: Experimental study of Bushen
Recipe on Th1/Th2 in liver tissue of chronic hepatic injury mice
model induced by ConA. China J Tradit Chin Med Pharm. 32:841–844.
2017.(In Chinese).
|
|
36
|
Xue D, Ma Y, Li M, Li Y, Luo H, Liu X and
Wang Y: Mycoplasma ovipneumoniae induces inflammatory response in
sheep airway epithelial cells via a MyD88-dependent TLR signaling
pathway. Vet Immunol Immunopathol. 163:57–66. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li X, Wang S, Zhu R, Li H, Han Q and Zhao
RC: Lung tumor exosomes induce a pro-inflammatory phenotype in
mesenchymal stem cells via NFkB-TLR signaling pathway. J Hematol
Oncol. 9:422016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gay NJ and Gangloff M: Structure and
function of Toll receptors and their ligands. Annu Rev Biochem.
76:141–165. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schwabe RF, Seki E and Brenner DA:
Toll-like receptor signaling in the liver. Gastroenterology.
130:1886–1900. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seki E and Brenner DA: Toll-like receptors
and adaptor molecules in liver disease: Update. Hepatology.
48:322–335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee MS and Kim YJ: Signaling pathways
downstream of pattern-recognition receptors and their cross talk.
Annu Rev Biochem. 76:447–480. 2007. View Article : Google Scholar : PubMed/NCBI
|
